Artículos de revistas
S100 Beta Is Associated With Cognitive Impairment In Childhood-onset Systemic Lupus Erythematosus Patients
Registro en:
Lupus. Sage Publications Ltd, v. 26, p. 478 - 483, 2017.
0961-2033
1477-0962
WOS:000399303800005
10.1177/0961203317691374
Autor
Lapa
A. T.; Postal
M.; Sinicato
N. A.; Bellini
B. S.; Fernandes
P. T.; Marini
R.; Appenzeller
S.
Institución
Resumen
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) To investigate serologic S100 beta protein levels in childhood-onset SLE patients (cSLE) and to elucidate their association with disease activity and neuropsychiatric (NP) manifestations. Methods: We included 71 cSLE patients (67 females; median age 18 years; range 9-37 and 53 (47 females; median age of 20 years; range 6-29) age and sex matched healthy controls. Neurological manifestations were analysed according to the American College of Rheumatology (ACR) criteria. Cognitive evaluation was performed in all participants using Wechsler Intelligence Scale for Children (WISC-III) and Wechsler Adult Intelligence Scale (WAIS), according to age, and validated in Portuguese. SLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity (SLE Disease Activity Index (SLEDAI)), damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)) and current drug exposures. Sera S100 beta protein levels were measured by enzyme-linked immunosorbent assay using commercial kits. Results: The median S100 beta protein level was 116.55 pg/mL (range 1.53-468.50) in cSLE and 54.98 pg/mL (range 0.69-181.00) in healthy controls (p<0.001). An association was observed between S100 beta protein and NP manifestations (p = 0.03). The S100 beta protein levels was associated with cognitive impairment in cSLE patients (p = 0.006). Conclusions: S100 beta protein levels are increased in cSLE with cognitive impairment. S100 beta may be considered a potential biomarker that underlies central nervous system (CNS) dysfunction, especially cognitive impairment. 26 5 478 483 Fundacao de Amparo a Pesquisa do Estado Sao Paulo-Brasil [FAPESP 2008/02917-0, 2011/03788-2] Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq [300447/2009-4, 471343/2011-0, 302205/2012-8, 473328/2013-5, 157534/2015-4] PANLAR Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)